Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol. 2007 Dec; 21(12):827-34.

View in: PubMed

subject areas

Administration, Oral
Adolescent
Adult
Aged
Anti-Inflammatory Agents, Non-Steroidal
Colitis, Ulcerative
Delayed-Action Preparations
Dose-Response Relationship, Drug
Double-Blind Method
Female
Follow-Up Studies
Humans
Male
Mesalamine
Middle Aged
Retrospective Studies
Severity of Illness Index
Sigmoidoscopy
Treatment Outcome

authors with profiles

Stephen B. Hanauer